FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Maccecchini Maria-Luisa 2. Issuer Name and Ticker or Trading Symbol Annovis Bio, Inc. [ ANVS ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President and CEO
(Last)         (First)         (Middle)
C/O ANNOVIS BIO, INC., 1055 WESTLAKES DRIVE, SUITE 300
3. Date of Earliest Transaction (MM/DD/YYYY)
12/6/2021
(Street)
BERWYN, PA 19312
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  $20.97  12/6/2021    A     112995      12/6/2021 (1) 12/6/2031  Common Stock  112995  $0  112995  D   
Stock Option (right to buy)  $20.97  12/6/2021    A     145305       (2) 12/6/2031  Common Stock  145305  $0  145305  D   

Explanation of Responses:
(1)  The stock option is 100% vested.
(2)  The stock option shall vest in two installments: (i) the first installment of 72,653 shares on March 31, 2022 and (ii) a second and final installment of 72,652 shares on March 31, 2023, provided that the reporting person continues to be employed by the issuer on the applicable vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Maccecchini Maria-Luisa
C/O ANNOVIS BIO, INC.
1055 WESTLAKES DRIVE, SUITE 300
BERWYN, PA 19312
X X President and CEO

Signatures
/s/ Jeffrey McGroarty, Attorney-in-Fact for Maria L. Maccecchini 12/8/2021
**Signature of Reporting Person Date
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Jul 2022 bis Aug 2022 Click Here for more Annovis Bio Charts.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Aug 2021 bis Aug 2022 Click Here for more Annovis Bio Charts.